Explore every episode of the podcast Perspectives: The Human Side of ALS Research
| Title | Pub. Date | Duration | |
|---|---|---|---|
| Enhancing the Patient Experience in ALS Research | 22 sept. 2026 | 00:30:43 | |
In the world of ALS research, the focus often lies on scientific rigor and data collection. Yet, as Corey Straub, a clincial development consultant who's worked in job is to enhance th patient experience, reminds us, the human experience of participating in clinical trials is equally significant. In this episode, Corey Straub shares insights on how small, human-centered changes in clinical trial experiences can significantly improve participant satisfaction, recruitment, and retention in ALS research. Topics
Summary
| |||
| Decoding Genetics: VUS SOS in ALS | 07 sept. 2026 | 00:37:56 | |
In this episode, Dr. Matthew Harms discusses the complexities of ALS genetics, focusing on variants of uncertain significance (VUS), the VUS Second Opinion Service, and how genetic insights are shaping ALS care and research Topics
| |||
| Looking Ahead with Dr. Senda Ajroud-Driss on Tofersen/Qalsody, Illuminate Series | 07 sept. 2026 | 00:41:17 | |
In this episode, Dr. Senda Ajroud-Driss discusses the journey of ALS research from gene discovery to targeted therapies, the importance of patient contributions, and the future of precision medicine in ALS care. Topics
| |||
| The Human Side of Research:Lori Hermstad and Erin Fleming, Illuminate Series. | 26 août 2026 | 01:11:42 | |
The development of jacifusen (ulefnersen) began with families affected by FUS-ALS coming together to help bring attention to this rare form of ALS. In this conversation, Lori Hermstad shares the lives and legacies of her daughters, Alex and Jaci, and the family’s extraordinary advocacy following two devastating ALS diagnoses. Erin Fleming, co-founder and COO of ProJenX and former Director of Research Operations at Project ALS, shares how Project ALS supported the Hermstad family and, alongside the ALS Association, helped fund the initial development of this investigational antisense oligonucleotide. Together, they discuss building a global community of FUS families, connecting with researchers, overcoming questions about whether this population was too small to study, and helping move a family-driven effort into a clinical development program that has now reached an international Phase 3 trial. This episode explores what the FUS story can teach the broader ALS field about rare genetic forms of disease, the importance of every subgroup, and the essential role impacted families play in shaping research and therapeutic development. | |||
| Genetics and the Lived Experience With Donna Bernstein, Illuminate Series | 11 août 2026 | 00:42:31 | |
Genetic Counselor Donna Bernstein and Dr. Nadia Sethi discuss genetics and genetic counseling and their impact on drug development and access to research. Their discussion highlights:
| |||
| Biomarkers in ALS with Dr. Michael Benatar, Illuminate Series | 20 juil. 2026 | 00:47:55 | |
Most ALS research today hinges on a simple question: how do we find reliable biomarkers that can unlock faster, more targeted drug development? Dr. Michael Benatar, an international leader in neuromuscular research unpacks the complex world of biomarkers, revealing why identifying and validating these biological tools has been such a challenge and why they are key to transforming ALS treatment. You'll discover how neurofilament light chain (NFL) is emerging as a promising prognostic and response biomarker, capable of predicting disease progress and evaluating therapy impact in real time. Dr. Benatar shares groundbreaking insights from his work on pre-symptomatic ALS and the CReATe Consortium, illustrating the steps from discovery to clinical validation. He breaks down the different types of biomarkers: diagnostic, prognostic, disease progression, predictive, and response, demystifying how each can shape your healthcare journey and research. If you're a person living with ALS, caregiver, researcher, or advocate eager for better treatments, this episode is essential. Don’t miss this vital conversation that could change how we fight ALS. | |||